Inclusion Criteria:

          1. Be ≥18 years old

          2. Have an established, pathologically confirmed diagnoses of CLL/ Small Lymphocytic
             Lymphoma (SLL) requiring therapy according to the 2018 IWCLL guidelines

          3. Have received at least one prior therapy for CLL/SLL and can be classified in one of
             two patient groups:

               -  Group 1 (TP-0903 monotherapy): Patients with CLL/SLL who are intolerant to, or
                  have progressed on B-cell receptor antagonists and/or BCL-2 antagonists or other
                  investigational treatments for CLL/SLL

               -  Group 2 (TP-0903 and ibrutinib combination therapy): Patients with CLL/SLL who
                  have progressed on ibrutinib, yet the treating provider considers continuation of
                  ibrutinib therapy to be in the best interest of the patient

          4. Have an Eastern Cooperative Oncology Group (ECOG) performance status ≤2

          5. Have adequate hematologic function:

               -  Absolute neutrophil count (ANC) ≥500/µL

               -  Platelet count ≥30,000/µL

               -  Hemoglobin ≥8 g/dL in the absence of transfusions within the previous 2 weeks

          6. Have adequate organ function:

               -  Creatinine clearance ≥30 mL/min

               -  Alanine aminotransferase (ALT)/aspartate aminotransferase (AST) level ≤2.5 ×
                  upper limit of normal (ULN)

               -  Have a total bilirubin level ≤1.5 × ULN (unless secondary to Gilbert syndrome,
                  hemolysis, or leukemia)

          7. Have acceptable coagulation status:

             • Activated partial thromboplastin (aPTT) and prothrombin time (PT) ≤1.5 × ULN

          8. Have a negative pregnancy test (if female of childbearing potential)

          9. Be nonfertile or agree to use an adequate method of contraception. Sexually active
             patients and their partners must use an effective method of contraception (hormonal or
             barrier method of birth control, or abstinence) prior to study entry and for the
             duration of study participation and for at least 30 days after the last study drug
             dose. Should a woman become pregnant or suspect that she is pregnant while
             participating in this study, she should inform her treating physician immediately.

         10. Have read and signed the Institutional Review Board (IRB) approved informed consent
             form (ICF) prior to any study related procedure. (In the event that the patient is
             rescreened for study participation or a protocol amendment alters the care of an
             ongoing patient, a new ICF must be signed.)

         11. Are able to comply with the requirements of the entire study

        Exclusion Criteria:

          1. Have undergone prior autologous or allogeneic stem cell transplant within ≤3 months,
             have not recovered from transplant associated toxicities, or requires graft versus
             host immunosuppressive therapy

          2. Have known central nervous system (CNS) involvement

          3. Have Richter's transformation of CLL

          4. Have received any monoclonal antibody therapy directed at treatment of the patient's
             malignancy within 2 weeks prior to anticipated first dose

          5. Have received any anticancer therapy including chemotherapy, radiotherapy, or an
             investigational anticancer drug within less than 5 half lives of the last dose of that
             treatment

             • This exclusion criterion is not applicable to patients requiring continuation on
             ibrutinib. (Note: Certain patients with a rapidly rising white blood cell count while
             on ibrutinib may need to remain on this drug for medical reasons. These patients will
             need to be approved by the Medical Monitor and treated in accordance with the
             protocol.)

          6. Have received >20 mg/day of prednisone and 0.1 mg/day of mineralocorticoids within 7
             days prior to anticipated first dose

          7. Have a corrected QT interval of >450 msec (males) and >470 msec (females) using
             Fridericia's correction formula

          8. Have a significant history of renal, neurologic, psychiatric, endocrinologic,
             metabolic, immunologic, hepatic, or cardiovascular disease or any other medical
             condition that, in the opinion of the Investigator, would adversely affect his/her
             participation in the study

          9. Are pregnant and/or nursing, or refuse to use appropriate contraceptives during the
             course of the study and for at least 30 days after the last dose of study drug

         10. History of another malignancy in the last 5 years except for the following adequately
             treated:

               -  Local basal cell or squamous cell carcinoma of the skin

               -  Carcinoma in situ of the cervix or breast

               -  Papillary, noninvasive bladder cancer

               -  Early stage prostate cancer for which observation is clinically indicated

               -  Other Stage 1 or 2 cancers currently in complete remission

               -  Any other cancer that has been in complete remission for 2 years or surgically
                  cured. Medical Monitor may be contacted for additional determination of
                  acceptable prior cancer history

         11. Have known gastrointestinal disorders (eg, malabsorption syndrome), complications (eg,
             dysphagia), or surgery that could make consumption or absorption of oral medications
             problematic

         12. Have an uncontrolled systemic infection (viral, bacterial, or fungal) or fever and
             neutropenia within 7 days prior to anticipated first dose

         13. Have active and uncontrolled autoimmune cytopenias for 2 or more weeks including
             autoimmune hemolytic anemia or idiopathic thrombocytopenic purpura (ITP)

         14. Have received prior therapy with an AXL inhibitor

         15. Have exhibited allergic reactions to a similar structural compound, biological agent,
             or formulation

         16. Are unwilling or unable to comply with procedures required in this protocol

         17. Have a history of severe adverse reaction (eg. hypersensitivity reaction, anaphylaxis)
             to sulfonamides